Cargando…
Successful treatment of idiopathic mast cell activation syndrome with low‐dose Omalizumab
OBJECTIVES: Idiopathic mast cell disorders, a recently defined and recognised syndrome in clinical practice, are similar to the previously termed non‐clonal mast cell disorder. Patients with idiopathic mast cell activation syndrome (MCAS) suffer all the classical signs of mast cell activation but do...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768441/ https://www.ncbi.nlm.nih.gov/pubmed/31576204 http://dx.doi.org/10.1002/cti2.1075 |